ACP
SRRA

Acuta Capital Partners’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Acuta Capital Partners’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-68,500
Closed -$1.49M – 47
2021
Q4 		$1.49M Buy
+68,500
New +$1.51M 0.63% 30

Other funds holding SRRA

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Acuta Capital Partners's SRRA Position: Q1 2022 in Review

Acuta Capital Partners sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q1 2022, closing a stake of 68,500 shares — an estimated $1.49M sold.

Acuta Capital Partners first reported a position in SRRA in Q4 2021 and held it in 1 quarter. The position peaked at $1.49M in Q4 2021. 75 funds tracked by Wall St. Rank hold SRRA as of Q1 2022.

  • Acuta Capital Partners reported no remaining Sierra Oncology, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Acuta Capital Partners sold 68,500 Sierra Oncology, Inc. Common Stock shares in Q1 2022, an estimated $1.49M.
  • Acuta Capital Partners first reported a position in Sierra Oncology, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Acuta Capital Partners's Sierra Oncology, Inc. Common Stock position peaked at $1.49M in Q4 2021.
  • 75 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q1 2022.

Based on Acuta Capital Partners's 13F filing for Q1 2022, filed 16 May 2022.